Mariner
ALLO icon

Mariner’s Allogene Therapeutics ALLO Stock Holding History

Mariner’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Sell
80,616
-28,106
-26% -$61.7K ﹤0.01% 3210
2026
Q1 		$265K Buy
108,722
+72,229
+198% +$145K ﹤0.01% 2978
2025
Q4 		$49.5K Sell
36,493
-177
-0.5% -$233 ﹤0.01% 3415
2025
Q3 		$45.5K Buy
+36,670
New +$43.7K ﹤0.01% 3458

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Mariner's ALLO Position: Q2 2026 in Review

Mariner reduced its Allogene Therapeutics (ALLO) stake by 26% in Q2 2026, selling an estimated $61.7K and leaving 80,616 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

Mariner first reported a position in ALLO in Q3 2025 and has held it in 4 quarters since. The position peaked at $265K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Mariner held 80,616 shares of Allogene Therapeutics worth $168K as of Q2 2026.
  • Mariner sold 28,106 Allogene Therapeutics shares in Q2 2026, an estimated $61.7K.
  • Allogene Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3210 holding.
  • Mariner first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Mariner's Allogene Therapeutics position peaked at $265K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.